WASHINGTON —
The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.
The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.
Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.
“This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it’s very kind and gentle on the patients — there’s no hair loss, no nausea, no vomiting,” said Dr. Melody Cobleigh of Rush University Medical Center. “It’s a revolutionary way of treating cancer.”
Cobleigh helped conduct the key studies of the drug at the Chicago facility.
The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.
The approval will help Roche’s Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.
Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.
FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.
Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.
FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer
Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.
Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug’s sales.
Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.
World, nation, state
FDA approves new breast cancer drug
- World, nation, state
-
-
Hoffa mystery still fascinates after 4 decades
The latest possible resting place of Teamsters boss Jimmy Hoffa is an overgrown farm field where the normal calm of chirping crickets is being drowned out by a beeping backhoe, the chop of an overhead news helicopter and the bustle of reporters and onlookers.
-
Three more plead guilty in probe of Pilot Flying J
Three more employees of the truck stop chain owned by the Cleveland Browns’ owner and Tennessee’s governor pleaded guilty Tuesday in what authorities call a scheme to cheat trucking firms out of rebates.
-
NSA surveillance helped foil more than 50 attacks, officials say
Recently disclosed National Security Agency surveillance programs have helped disrupt more than 50 “potential terrorist events” around the world over the last 12 years, according to U.S. intelligence officials who described the spying operations as tightly regulated and extremely useful.
-
Military plans would put women in most combat jobs
Women may be able to start training as Army Rangers by mid-2015 and as Navy SEALs a year later under plans set to be announced by the Pentagon that would slowly bring women into thousands of combat jobs, including those in elite special operations forces.
-
Jurors share concerns, and opinions, on Trayvon Martin shooting
Seminole County residents poured into the criminal courthouse in Florida last week as potential jurors for the trial of George Zimmerman. By the dozens, most were sent back home.
-
Internal Revenue Service supervisor in DC scrutinized tea party cases
An Internal Revenue Service supervisor in Washington says she was personally involved in scrutinizing some of the earliest applications from tea party groups seeking tax-exempt status, including some requests that languished for more than a year without action.
-
Poll finds most men aspire to be fathers
A recent Associated Press-WE tv poll found more than 8 in 10 men said they have always wanted to be fathers or think they’d like to be one someday.
-
New evidence being checked in Cleveland kidnapping case
A state crime laboratory is checking new evidence to determine if there were additional victims of a man charged with kidnapping three women and raping them in his home over a decade, the Ohio attorney general said Friday.
-
Steubenville football player classified as sex offender
A high school football player convicted of raping a 16-year-old girl after an alcohol-fueled party last summer was given the state’s second-toughest sex offender classification at a Friday hearing.
-
Charla Nash denied permission to sue Connecticut over 2009 chimp attack
A multimillion-dollar claim against the state of Connecticut by Charla Nash — blinded in a 2009 mauling by a 200-pound chimpanzee that tore off her face — was dismissed Friday by state Claims Commissioner J. Paul Vance Jr.
- More World, nation, state Headlines
-
